Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Endeavour Silver Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.83 (market cap $8.04B), while Endeavour Silver Corp trades at $8.02 (market cap $2.39B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.4× Endeavour Silver Corp's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| BIO | EXK | |
|---|---|---|
Market Cap | $8.04B | $2.39B |
Sector | Health | Basic Materials |
52-Week High | $339.75 | $14.12 |
52-Week Low | $241.71 | $4.96 |
Enterprise Value | $7.85B | $2.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
EXK trades at $7.84, down 2.97% on the day, amid a bearish technical signal. The company reported strong Q1 2026 results with earnings of $0.21 per share beating estimates, driven by record production. However, full-year 2025 financials show a net loss of $119.10 million. Analyst sentiment is largely positive with 11 buy ratings, but the stock faces headwinds from negative profitability metrics and high valuation multiples.
The outlook is mixed; operational improvements and silver price trends offer upside, but persistent losses and bearish technicals pose risks. Investors should weigh the company's growth potential against its current financial health and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
